共 38 条
Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study
被引:0
作者:
Renke, Marcin
[1
]
Tylicki, Leszek
[1
]
Rutkowski, Przemyslaw
[1
]
Knap, Narcyz
[2
]
Zietkiewicz, Marcin
[3
]
Neuwelt, Alexander
[4
]
Aleksandrowicz, Ewa
[5
]
Lysiak-Szydlowska, Wieslawa
[5
]
Wozniak, Michal
[2
]
Rutkowski, Boleslaw
[1
]
机构:
[1] Med Univ Gdansk, Dept Nephrol Transplantol & Internal Med, Gdansk, Poland
[2] Med Univ Gdansk, Dept Med Chem, Gdansk, Poland
[3] Med Univ Gdansk, Dept Internal Med Connect Tissue Dis & Geriatr, Gdansk, Poland
[4] Oregon Hlth & Sci Univ, Blood Brain Barrier & Neurooncol Program, Portland, OR 97201 USA
[5] Med Univ Gdansk, Dept Clin Nutr & Lab Diagnost, Gdansk, Poland
关键词:
pentoxifylline;
oxidative stress;
kidney;
chronic kidney disease;
proteinuria;
tubular injury;
ACETYL-BETA-GLUCOSAMINIDASE;
C-REACTIVE PROTEIN;
RENIN-ANGIOTENSIN SYSTEM;
DOSE DUAL BLOCKADE;
PRIMARY GLOMERULONEPHRITIS;
THERAPEUTIC EFFICACY;
RECEPTOR ANTAGONISTS;
CELLS;
DYSFUNCTION;
PROGRESSION;
D O I:
暂无
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Background: Inhibition of the renin-angiotensin-aldosterone system (RAAS) with angiotensin converting enzyme inhibitors (ACEI) and/or angiotensin II subtype 1 receptor antagonists (ARB) is a common strategy used in the management of patients with chronic kidney disease (CKD). However, there is no universal therapy that can stop progression of CKD. Pentoxifylline (PTE) is a nonspecific phosphodiesterase inhibitor with anti-inflammatory properties. It has been reported to have promising effects in CKD treatment. Methods: In a placebo-controlled, randomized, cross-over study we evaluated the influence of PTE (1200 mg/day) added to RAAS blockade on proteinuria, surrogate markers of tubular injury and oxidative stress-dependent products in 22 non-diabetic patients with proteinuria (0.4-4.3 g per 24 h) with normal or declined kidney function [eGFR 37-178 mL/min]. In an eight-week run-in period, therapy using ACEI and/or ARB was adjusted to achieve a blood pressure below 130/80 mm Hg. Next, patients were randomly assigned to one of two treatment sequences: PTE/washout/placebo or placebo/washout/PTE. Clinical evaluation and laboratory tests were performed at the randomization point and after each period of the study. Results: The PTE therapy reduced proteinuria (by 26%) as compared to placebo. There were no differences in alpha(1)-microglobulin, urine excretion of N-acetyl-beta-D-glucosaminidase (NAG), hsCRP, the urinary excretion of 15-F-2t-isoprostane, blood pressure (BP), eGFR and serum creatinine between the PTE and placebo groups. Conclusion: Pentoxifylline may decrease proteinuria in non-diabetic patients with CKD.
引用
收藏
页码:119 / 123
页数:5
相关论文